Intralymphatic histiocytosis in a patient with lung adenocarcinoma treated with pembrolizumab: a case report

被引：8

作者：

Sugano, Teppei ^{[1
]}

Seike, Masahiro ^{[1
]}

Funasaka, Yoko ^{[2
]}

Yoshida, Mai ^{[2
]}

Takayama, Ryoko ^{[2
]}

Okamura, Ken ^{[1
]}

Nakanishi, Asuka ^{[1
]}

Tanaka, Toru ^{[1
]}

Takeuchi, Susumu ^{[1
]}

Noro, Rintaro ^{[1
]}

Minegishi, Yuji ^{[1
]}

Kubota, Kaoru ^{[1
]}

Saeki, Hidehisa ^{[2
]}

Gemma, Akihiko ^{[1
]}

机构：

[1] Nippon Med Sch, Grad Sch Med, Dept Pulm Med & Oncol, Bunkyo Ku, 1-1-5 Sendagi, Tokyo 1138603, Japan

[2] Nippon Med Sch, Dept Dermatol, Tokyo, Japan

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2019年 / 7卷

关键词：

Lung adenocarcinoma; Pembrolizumab; Intralymphatic histiocytosis; IMMUNE CHECKPOINT BLOCKADE; CUTANEOUS ADVERSE EVENTS; INTRAVASCULAR HISTIOCYTOSIS; INFLIXIMAB; NIVOLUMAB;

D O I：

10.1186/s40425-019-0534-z

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BackgroundPembrolizumab, an anti-programmed cell death-1 protein monoclonal antibody, is effective for patients with advanced non-small-cell lung cancer. However, immune checkpoint inhibitors such as pembrolizumab induce various immune-related adverse events, involving the lung, liver, gastrointestinal, endocrine system, and skin. Intralymphatic histiocytosis (ILH) is a rare, chronic cutaneous disorder with a reactive inflammatory component, which often occurs in patients with rheumatoid arthritis.Case presentationWe present a 67-year-old man with lung adenocarcinoma who developed ILH associated with pembrolizumab treatment. He was treated with palliative thoracic radiotherapy for superior vena cava syndrome. Subsequently, he received four cycles of pembrolizumab. Approximately 2.5months after the initiation of pembrolizumab, he developed erythema on the trunk of his body. Based on findings of skin biopsies, he was diagnosed with pembrolizumab-induced ILH. Moreover, the upregulation of tumor necrosis factor- was observed during pembrolizumab therapy.ConclusionsThis is the first report of ILH induced by pembrolizumab in a patient with lung adenocarcinoma.

引用

页数：5

共 20 条

[1] Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Yokoi, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

de Castro Carpeno, J. ;

Wadsworth, C. ;

Melillo, G. ;

Jiang, H. ;

Huang, Y. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) :1919-1929

[2] Primary and secondary intralymphatic histiocytosis [J].

Bakr, Farrah ;

Webber, Naomi ;

Fassihi, Hiva ;

Swale, Victoria ;

Lewis, Fiona ;

Rytina, Ed ;

Ben-Zvi, Galia Tamar ;

Norris, Paul ;

Espinosa, Olivia ;

Dhar, Sunanda ;

Craig, Paul ;

Robson, Alistair .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 70 (05) :927-933

[3] Intralymphatic Histiocytosis: A case report and review of literature [J].

Barba, Eleonora ;

Colato, Chiara ;

Girolomoni, Giampiero .

JOURNAL OF CUTANEOUS PATHOLOGY, 2015, 42 (09) :593-599

[4] Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary [J].

Brahmer, Julie R. ;

Lacchetti, Christina ;

Thompson, John A. .

JOURNAL OF ONCOLOGY PRACTICE, 2018, 14 (04) :247-+

[5] Diverse types of dermatologic toxicities from immune checkpoint blockade therapy [J].

Curry, Jonathan L. ;

Tetzlaff, Michael T. ;

Nagarajan, Priyadharsini ;

Drucker, Carol ;

Diab, Adi ;

Hymes, Sharon R. ;

Duvic, Madeleine ;

Hwu, Wen-Jen ;

Wargo, Jennifer A. ;

Torres-Cabala, Carlos A. ;

Rapini, Ronald P. ;

Prieto, Victor G. .

JOURNAL OF CUTANEOUS PATHOLOGY, 2017, 44 (02) :158-176

[6] Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy [J].

Grimaldi, Antonio M. ;

Simeone, Ester ;

Giannarelli, Diana ;

Muto, Paolo ;

Falivene, Sara ;

Borzillo, Valentina ;

Giugliano, Francesca Maria ;

Sandomenico, Fabio ;

Petrillo, Antonella ;

Curvietto, Marcello ;

Esposito, Assunta ;

Paone, Miriam ;

Palla, Marco ;

Palmieri, Giuseppe ;

Caraco, Corrado ;

Ciliberto, Gennaro ;

Mozzillo, Nicola ;

Ascierto, Paolo A. .

ONCOIMMUNOLOGY, 2014, 3 (05)

[7] Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial [J].

Herbst, Roy S. ;

Baas, Paul ;

Kim, Dong-Wan ;

Felip, Enriqueta ;

Perez-Gracia, Jose L. ;

Han, Ji-Youn ;

Molina, Julian ;

Kim, Joo-Hang ;

Arvis, Catherine Dubos ;

Ahn, Myung-Ju ;

Majem, Margarita ;

Fidler, Mary J. ;

de Castro, Gilberto, Jr. ;

Garrido, Marcelo ;

Lubiniecki, Gregory M. ;

Shentu, Yue ;

Im, Ellie ;

Dolled-Filhart, Marisa ;

Garon, Edward B. .

LANCET, 2016, 387 (10027) :1540-1550

[8] Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort [J].

Hwang, Shelley Ji Eun ;

Carlos, Giuliana ;

Wakade, Deepal ;

Byth, Karen ;

Kong, Benjamin Y. ;

Chou, Shaun ;

Carlino, Matteo S. ;

Kefford, Richard ;

Fernandez-Penas, Pablo .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (03) :455-+

[9] Immune-related adverse events with immune checkpoint blockade: a comprehensive review [J].

Michot, J. M. ;

Bigenwald, C. ;

Champiat, S. ;

Collins, M. ;

Carbonnel, F. ;

Postel-Vinay, S. ;

Berdelou, A. ;

Varga, A. ;

Bahleda, R. ;

Hollebecque, A. ;

Massard, C. ;

Fuerea, A. ;

Ribrag, V. ;

Gazzah, A. ;

Armand, J. P. ;

Amellal, N. ;

Angevin, E. ;

Noel, N. ;

Boutros, C. ;

Mateus, C. ;

Robert, C. ;

Soria, J. C. ;

Marabelle, A. ;

Lambotte, O. .

EUROPEAN JOURNAL OF CANCER, 2016, 54 :139-148

[10] WHOLE BODY IRRADIATION - RADIOBIOLOGY OR MEDICINE [J].

MOLE, RH .

BRITISH JOURNAL OF RADIOLOGY, 1953, 26 (305) :234-241

← 1 2 →